Biognosys believe that the decoding of the proteome will impact the life sciences more than the genome revolution a decade ago, and they strive to be the company that enables the routine analysis of proteomes in each research and clinical laboratory worldwide.

Biognosys offers a unique next-generation solution for precise quantification of large proteomes in biological samples. Their technology provides unprecedented DEBTh and quality of protein expression data for more effective biomarker and drug-target discovery and validation.
Biognosys is a spin-off from the leading proteomics lab of Prof. Ruedi Aebersold, ETH Zurich.